Treatment of Relapsed Wilms’ Tumor With High-Dose Therapy and Autologous Hematopoietic Stem-Cell Rescue: The Experience at Children’s Memorial Hospital

Abstract

Our results suggest that HDT with HSCR is an effective treatment for patients with Wilms' tumor who experience relapse.

Value and difficulties of a common European strategy for recurrent Wilms’ tumor

“…The introduction of these drugs into intensive chemotherapy regimens or high-dose therapy with autologous stem-cell rescue (ASCR) led to DFS rates ranging between 50 and 70% for children with recurrent WT [9][10][11][12][13][14][15].…”

“…Trials with high-dose chemotherapy and ASCR obtained a better outcome than historical controls, with 3 or 4-year OS rates ranging from 60 to 73% [9][10][11]14,15].…”

Clinical Factors in Relapses of Wilms’ Tumor – Results for the Polish Pediatric Solid Tumors Study Group

“…Among other things, Abu-Ghosh et al reported a good response in children treated with ICE (ifosfamide, carboplatin, etoposide) [13]. In a study by Cambell et al, after applying megachemotherapy and autologous stem cell transplant, a 4-year survival free of relapse was achieved in about 60% of the cases, and a total 4-year survival rate of 73% [14]. There was no evidence that the transplant itself was associated with increased mortality.…”

Late recurrence of Wilms’ tumour with exclusive skeletal muscle phenotype 23 years after primary diagnosis

“…The recurrence risk is greater within the first 2 years after primary diagnosis (in these patients the percentage of survival approximaly ranges from 24% to 43%) but late relapses have occasionally been reported [1,10].…”